SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Theragenics (TGX) on the up and up
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark3000 who wrote (941)7/6/1998 9:32:00 AM
From: joe caetano  Read Replies (1) of 1055
 
Great Wall ST Journal article on THRX today. 07-06-1998

WE are going up as shorts close out and the recent downgrade is disputed by Salomon Smith Barney and the CEO of the Co.

here are some of the tidbits from the Wall St article


Jul 6 1998
###############################################################

Shares of THRX plunged 36 % after an analyst raised doubts about prospects for the maker of medical
radiological devices.
Thrx executives as well as other analysts disputed the analyst's position. Never the less THRX shares fell 0n
NASDAQ
stock market trading to close at 14.183 down 8.188

*************THIS WAS A WALL ST MISPRINT BECAUSE WE ALL KNOW IT
DID NOT FINISH THIS LOW ************************

The sellof began after Parice Halbert............(DO I HAVE TO RESTATE THIS AGAIN>>>>>I THINK
NOT )

THRX Chairman and CEO M.CHRISTINE JACOBS said " It's an unfortunate conclusion drawn from a
single paper from a single
physician" adding that other research refutes the conclusions
of the journel article. It's triggered a selloff in a jittery
violate market. We have no revisions,No restatements,No corporate developments of any kind.
Thrx based in Norcross GA posted net income of 9.5 million
on sales of 24.6 million in 1997
Analyst Melissa Wilmoth At Salomon Smith Barney Said the stocks fall was accelerated by short sellers and
created a HUGH
buying opportunity.
Alot of what is behind the Bain Rausher downgrade is speculation and promises from companies that are not
even in this
market yet, Ms Wilmoth said. She said THRX continues to have strong sales and that the company has
received approval to begin using brachytherapy in treating other types of cancer.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News